JAMA : the journal of the American Medical Association
-
Randomized Controlled Trial Multicenter Study
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain. ⋯ Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support-free days within 21 days.